Jianbo Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3191161/publications.pdf

Version: 2024-02-01

		1040056	996975
17	409	9	15
papers	citations	h-index	g-index
18	18	18	919
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review. Critical Care, 2021, 25, 115.	5.8	86
2	The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex. Journal of Biological Chemistry, 2020, 295, 2698-2712.	3.4	9
3	Mutations in <i><scp>TOP</scp>2B</i> cause autosomalâ€dominant hereditary hearing loss <i>via</i> inhibition of the <scp>PI</scp> 3Kâ€Akt signalling pathway. FEBS Letters, 2019, 593, 2008-2018.	2.8	13
4	Novel TRRAP mutation causes autosomal dominant nonâ€syndromic hearing loss. Clinical Genetics, 2019, 96, 300-308.	2.0	11
5	Functional analysis of a de novo mutation c.1692 del A of the PHEX gene in a Chinese family with X-linked hypophosphataemic rickets. Bone and Joint Research, 2019, 8, 405-413.	3.6	1
6	Specific prognostic factors in hepatitis B virusâ€related and nonâ€hepatitis B virus–related intrahepatic cholangiocarcinoma after macroscopic curative resection. Journal of Surgical Oncology, 2019, 119, 40-46.	1.7	11
7	Epigenetic regulation of megakaryocytic and erythroid differentiation by PHF2 histone demethylase. Journal of Cellular Physiology, 2018, 233, 6841-6852.	4.1	7
8	Paired box 5 is a novel marker of breast cancers that is frequently downregulated by methylation. International Journal of Biological Sciences, 2018, 14, 1686-1695.	6.4	7
9	New role of LRP5, associated with nonsyndromic autosomal-recessive hereditary hearing loss. Human Mutation, 2017, 38, 1421-1431.	2.5	8
10	The prevalence and clinicopathological features of breast cancer patients with hepatitis B virus infection in China. Oncotarget, 2017, 8, 18185-18190.	1.8	10
11	The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer. Oncotarget, 2017, 8, 108249-108260.	1.8	23
12	Chrysin inhibits metastatic potential of human tripleâ€negative breast cancer cells by modulating matrix metalloproteinaseâ€10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. Journal of Applied Toxicology, 2014, 34, 105-112.	2.8	85
13	DACT1, an antagonist to Wnt \hat{l}^2 -catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. Breast Cancer Research, 2013, 15, R23.	5.0	83
14	Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine. BMC Cancer, 2013, 13, 334.	2.6	49
15	Neo-endocrinochemotherapy: A novel approach for enhancing chemotherapeutic efficacy in clinic?. Medical Hypotheses, 2013, 80, 441-446.	1.5	6
16	Effect of chemotherapy before or after termination in pregnancy-associated breast cancer patients: two cases report. Chinese-German Journal of Clinical Oncology, 2013, 12, 96-98.	0.1	0
17	Progress in the study of cancer-associated retinopathy in breast cancer patients. Chinese-German Journal of Clinical Oncology, 2012, 11, 566-571.	0.1	0